This health-care ETF is heavy on service providers and light on pharmaceutical firms.
The unique weighting scheme of this biotech ETF ensures that no single holding will engulf its index.
With large biotechs dominating this ETF, look elsewhere for the more exciting, smaller-cap biotechs.
This equal-weight ETF offers balanced exposure to a basket of pharmaceutical firms.
This ETF offers relatively broad exposure to the notoriously volatile but promising biotech industry.
This ETF's equal-weight structure translates into heavier exposure to small- and mid-cap biotechs.
This equal-weighted ETF allows investors to gain biotech exposure without assuming firm-specific risk.
Aside from being heavily dependent on disposable household income and consumer spending, the firms in this portfolio are also susceptible to changes in demographics and fickle consumer tastes.High gas prices may crowd out other forms of consumer spending.This fund is a very low-cost retail-focused
This targeted ETF invests almost 70% of assets in companies with economic moats.
This ETF offers pure-play exposure to Internet commerce and services companies.